Mode
Text Size
Log in / Sign up

Feasibility of Trans-aqueduct Access to Third Ventricle via Minimally Invasive Techniques in MRI and Cadaveric SpecimensNew Pathway Opens Doors to Deep Brain Therapy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that physiological tolerance and safety require further evaluation before considering this pre-clinical feasibility data.

This pre-clinical feasibility study utilized human MRI datasets (n=16; mean age 48.4 years) and cadaveric specimens (n=6; mean age 88.2 years) to assess technical feasibility of retrograde access. The intervention involved trans-aqueduct access to the third ventricle via minimally invasive interventional techniques using fluoroscopically guided guidewires and catheters. No comparator was reported.

Primary outcomes focused on technical feasibility and morphometric analysis. Secondary outcomes included localization of STN and GPi relative to the ventricular volumetric centroid. Successful access to the third ventricle occurred in 83% of cases (5/6). Mean aqueduct diameter was 1.6 mm (SD=0.14), with an accommodation diameter up to 2.0 mm. Third ventricle dimensions measured 27.6 mm (ventral-dorsal), 19.9 mm (caudal-cranial), and 5.7 mm (lateral). The distance from the ventricular volumetric centroid to STN and GPi ranged from 5-20 mm.

Safety data were not reported, including adverse events or discontinuations. Tolerability requires further pre-clinical investigation to evaluate physiological tolerance, trauma risk, and long-term implications of intraventricular implantation. The study was conducted in human MRI datasets and cadaveric specimens only, limiting generalizability.

Certainty is low due to the pre-clinical nature and lack of physiological or clinical outcome data. Feasibility does not imply safety. While offering a potential alternative for the delivery of therapeutic neurotechnologies, clinical relevance remains uncertain pending further evaluation.

Subheading: Why doctors need a better way

Conditions like Parkinson’s disease affect how you move. Doctors often use deep brain stimulation to help. But getting there usually requires drilling into the skull. Many patients worry about the risks of big cuts. Infection and bleeding are real concerns for older adults. Finding a safer route could change lives for the better.

Subheading: The surprising shift in surgery

For years, the only way was through the top of the head. This creates a larger opening for infection or bleeding. But here’s the twist. A new study shows a hidden tunnel inside the brain. It uses a natural passage that was already there. This avoids cutting through the brain tissue itself.

Subheading: How the tunnel works

Think of your brain like a house with locked rooms. The third ventricle is a central hallway near important parts. This new method uses a tiny tube to slide through. It avoids cutting through the brain tissue itself. Imagine walking through a door instead of breaking a wall. The tube follows a narrow channel called the aqueduct. This channel connects different parts of the brain fluid system. It acts like a small pipe inside a busy house.

Subheading: Study details in plain English

Scientists looked at brain scans from sixteen people. They also tested the path on six human tissue samples. They measured the space carefully to ensure safety. The samples were older, which helps understand aging brains. They used special wires to test the path. This helped them see if tools could fit through. The team checked the size of the tunnel first.

Subheading: What the numbers mean for patients

They successfully reached the target area in most cases. Eighty-three percent of the tests worked perfectly. The path was wide enough for small medical tools. Important targets sat just a few millimeters away. This distance is very small, like the width of a pencil. It means the device can reach deep areas easily. Doctors can place wires without going through the brain. The targets control movement and are hard to reach.

Subheading: What experts are saying

Experts say this is a promising first step. It offers hope for safer procedures in the future. However, human bodies are more complex than models. Living tissue moves and reacts differently than dead tissue. We need to know if the body accepts the tube. Long-term safety is the biggest question right now. This doesn’t mean this treatment is available yet.

Subheading: What this means for you

You cannot get this procedure today. It is still in the research phase. Talk to your doctor about current options. If you have a movement disorder, ask about standard care. Do not wait for this new method to get help. Current treatments are proven to work for many people. Your doctor knows your specific health history best.

Subheading: The study has limits

The study used dead tissue, not living people. We do not know how the body reacts long-term. Safety risks like bleeding need more checking. The human skull is different from the models used. Inflammation could happen inside the brain fluid. We need to see how the body heals over time. Blood vessels could be damaged in a living person.

Subheading: The road ahead

Researchers will test this on living animals next. Approval takes years of careful safety checks. But the path to better care is opening up. Clinical trials will start once safety is confirmed. This could lead to smaller surgeries for patients. Science moves slowly, but every step counts. We are watching closely for the next updates.

Study Details

Study typePhase3
Sample sizen = 16
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
This research demonstrates that the trans-aqueduct approach is a feasible, minimally invasive access pathway to the third ventricle, offering a potential route to the deep brain for therapeutic technologies. Further pre-clinical investigation is required to thoroughly evaluate physiological tolerance, trauma risk, and the long-term implications of intraventricular implantation. The third ventricle is a high-value site for neuromodulation due to its proximity to deep-brain targets, including the subthalamic nucleus (STN) and globus pallidus internus (GPi). This study defined the anatomical pathway; and evaluated the technical feasibility of retrograde access to the third ventricle via the cerebral aqueduct using minimally invasive interventional techniques. Evaluation was conducted in three phases using human MRI datasets (n=16; mean age 48.4 years) and cadaveric specimens (n=6; mean age 88.2 years). Phase 1 involved morphometric MRI analysis of the aqueduct and ventricles. Phase 2 tested trans-aqueduct access on cadaver specimens via fluoroscopically guided guidewires and catheters. Phase 3 utilized direct anatomical dissections on cadaver specimens (n=3) to morphometrically measure the third ventricular cavity and its relationship to deep-brain nuclei. Measurements across the sample groups showed a mean aqueduct diameter of 1.6 mm (SD=0.14). Third ventricle dimensions averaged 27.6 mm (ventral-dorsal), 19.9 mm (caudal-cranial), and 5.7 mm (lateral). Successful access to the third ventricle was achieved in 83% (5/6) of cadaveric specimens. The optimal technical configuration utilized a 0.018'' angled-tip guidewire and 5-6 Fr catheters; the aqueduct accommodated diameters up to 2.0 mm with minimal resistance. The STN and GPi were localized within 5-20 mm of the ventricular volumetric centroid. The trans-aqueduct approach is a technically feasible, minimally invasive pathway for accessing the third ventricle. This route offers a potential alternative for the delivery of therapeutic neurotechnologies. Further research is required to assess physiological tolerance, trauma risk, and the long-term safety of intraventricular implantation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.